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Abstract: Mood depression is a common and serious complication after stroke. According 
to epidemiological studies, nearly 30% of stroke patients develop depression, either in the 
early or in the late stages after stroke. Although depression may affect functional recovery and 
quality of life after stroke, such condition is often ignored. In fact, only a minority of patients is 
diagnosed and even fewer are treated in the common clinical practice. Moreover, the real beneﬁ  ts 
of antidepressant (AD) therapy in post-stroke depression have not been fully clariﬁ  ed. In fact, 
controlled studies on the effectiveness of ADs in post stroke depression (PSD) are relatively 
few. Today, data available suggest that ADs may be generally effective in improving mood, 
but guidelines for the optimal treatment and its length are still lacking.
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The progressive decrease in stroke mortality observed in Western countries, in the 
last decades, and the subsequent increase of survivors with residual impairments and 
disabilities (Sarti et al 2000), have been accompanied by a growing interest in factors 
that could interfere with functional outcome and quality of life (QoL). In light of this, 
a crucial role is played by post-stroke depression (PSD).
In particular, mood depression is considered as the strongest predictor of QoL 
in stroke survivors (Kim et al 1999; King 1996). Moreover, PSD is associated with 
an increased disability ( Schwartz et al 1993; Herrmann et al 1998; Ramasubbu et al 
1998; Kotila et al 1999; Pohjasvaara et al 2001), increased cognitive impairment 
(Kauhanen et al 1999), increased mortality, both on short and long term (Morris et al 
1993; Schulz et al 2000; House et al 2001; Williams et al 2004), increase risk of falls 
(Jorgensen et al 2002) and, ﬁ  nally, with worse rehabilitation outcome (Sinyor et al 
1986; Paolucci et al 1999, 2001; van de Weg et al 1999; Gillen et al 2001). Conversely, 
the absence of PSD in young adults is a signiﬁ  cant predictor of the ability to return 
to work (Neau et al 1998). Moreover, an improvement of depressive symptoms has 
been associated with a better functional recovery (Chemerinski et al 2001).
In spite of the relative large number of papers available on PSD, it is surprising 
to note that the attention of authors has been focused on epidemiological features 
and impact of PSD both on functional outcome and QoL than on possible therapeutic 
approaches.
This review concerns a literature evaluation on epidemiological and therapeutic 
aspects of PSD. Relevant articles related to depression and cerebrovascular diseases 
selected from computer-based search have been examined using the Medline database 
from 1975 to August 2007.
Epidemiological dimension 
and methodological problems
Today, in spite of the abundant literature available on this topic, it is still difﬁ  cult to 
deﬁ  ne the real prevalence rate of PSD, essentially because of the weak concordance Neuropsychiatric Disease and Treatment 2008:4(1) 146
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across studies. This relevant variability arises not only from 
methodological problems of the investigations (differences 
in study populations and the timing of assessments) but also 
from the complexity in recognition, assessment, and diagnosis 
of depression.
In fact, as shown in the Table 1, there is a large variability 
of diagnostic tools used for the detection of PSD. In fact, while 
most of the studies based the diagnosis on cutoff score in differ-
ent rating scales, others followed a structured interview and the 
diagnostic standards deﬁ  ned by DSM (Diagnostic and statistical 
manual of mental disorders)-III, III-R, and IV, and some studies 
even based their assessment only on clinical ﬁ  ndings.
Moreover, assessment of depression in stroke survivors 
may be often laborious and the risk of inappropriate diagnosis 
(under- or overdiagnosing) is high (Fedoroff et al 1991). 
In fact, PSD may not only be overdiagnosed because of 
somatic symptoms caused by medical illness, but also 
underdiagnosed, particularly in patients with cognitive 
impairment. Another problem, as observed by Schubert and 
coworkers (1992), may be the inadequacy of physicians 
without a proper psychiatric training (Schubert et al 1992). 
The correct attribution of somatic symptoms (psychomotor 
retardation, and disturbances in appetite, sleep, and sexual 
interest) to either PSD or stroke is a very relevant problem, 
because such symptoms may affect rating scales, as Hamilton 
Depression Rating Scale (HDRS), Montgomery Asberg 
Depression Rating Scale (MADRS), or Beck Depression 
Inventory (BDI), and also because they are among DSM 
criteria. It is important to remember that rating scales 
were designed to measure depression severity in primary 
depressive illness, rather than to diagnose depression, in 
particular for depression in comorbidity. Furthermore, DSM 
criteria for classiﬁ  cation of disorders, (temporal criteria, 
in particular) are not always satisﬁ  ed for dysthymia and 
major depression. So, we found cases diagnosed as major 
depression even in reports on PSD in settings characterized 
by short hospital stay, such as stroke units (Kellermann et al 
1999; Berg et al 2001). Additionally, other relevant points, 
as evaluation-time after stroke (acute vs. chronic patients) 
and variability of the study setting (in-patients, outpatients, 
patients bedridden in rehabilitation structures, community), 
minimize the possibility of a generalization. Lastly, the 
problem of aphasia should be kept in mind. The exclusion 
of aphasic patients, because of the evident difﬁ  culty in 
evaluating depressive symptoms, reported in several of 
studies examined, may be an important confounding variable 
(Carson et al 2000). However, there is no concordance on 
frequency of PSD in aphasics, observed either in low (15%) 
(Damecour and Caplan 1991), in middle (24%) (Laska et al 
2007) and in high percentage (70% at 3 months and 62% at 
12 months after stroke) of cases (Kauhanen et al 2000).
A recent meta-analysis, evaluating data from studies 
conducted between 1977 and 2002, estimated the pooled 
frequency at 33% (95% conﬁ  dence interval, 29% to 36%) 
(Hackett et al 2005b), even if with relevant differences 
across studies. In particular, the pooled estimate from 
the population-based studies was equal in the acute and 
medium-term phases (33%), with a slight increase to 34% 
in the long-term phase of recovery after stroke. Moreover, 
there were only slight differences in the pooled frequencies 
in the hospital-based (acute 36%, medium-term 32%, and 
long-term 34%) and rehabilitation-based studies (acute 30%, 
medium 36%, and long-term 34%) over time.
Studies available after the publication of that report con-
ﬁ  rmed that PSD is generally observed in nearly one third of 
cases (Vataja et al 2004; Verdelho et al 2004; Paolucci et al 
2006; Linden et al 2007; Townend et al 2007). However, a 
certain degree of variability in the percentages was observed 
in those reports, too. In particular, the percentage of depres-
sion observed in the Sidney Stroke Study was lower than in 
the previous ones (Brodaty et al 2007). Moreover, recent 
longitudinal studies observed not only that frequency PSD 
increases in prevalence over the initial weeks post-stroke, 
in particular within three months from stroke, despite an 
improvement in disability (Andersen et al 1994b; Aben et al 
2003; Paolucci et al 2006), but also that patients with early 
onset PSD were not necessarily affected later and vice versa, 
indicating the dynamic nature of PSD in the early stages.
Only few epidemiological data on vascular depression 
are available today. Vascular depression is a new diagnostic 
concept based on hypothesis that chronic ischemic damage 
is an important cause of depression in the elderly. This 
concept initially emerged from the ﬁ  nding that patients with 
late-onset depression had higher rate of encephalomalacia 
or hyperintensities observed with magnetic resonance 
imaging (MRI) compared with patients with early-onset 
depression (Hickie et al 1995), and was later formulated 
by Alexopoulos and coworkers in 1997. These authors 
hypothesized that cerebrovascular disease can predispose, 
precipitate, or perpetuate a depressive syndrome in older 
adults (Alexopoulos et al 1997a). Affected individuals 
display more apathy, retardation, and lack of insight, and 
less agitation and guilt than do elderly individuals who 
are depressed without vascular risk factors, on one hand, 
and also greater disability and cognitive impairment, on 
the other (Alexopoulos et al 1997b). Mast and coworkers Neuropsychiatric Disease and Treatment 2008:4(1) 147
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Table 1 Prevalence of PSD according to time and setting of evaluation
Authors n  Population  Country  Time  Criteria  %
Folstein et al 1977  20  Rehab hosp  USA  1 m  HDRS/PSE  45
Robinson et al 1981  18  hospital-based  USA   1 m  HDRS, ZSRDS  61
Feibel et al 1982  91  outpatient  USA   6 m  Nursing evaluation  26
Robinson et al 1983  103  hospital-based  USA  1 m  HDRS, PSE,DSM-III  47
Sinyor et al 1986  64  Rehab hosp  CND   2 m  ZSRDS  47
Ebrahim et al 1987  149  hospital-based  UK  6 m  GHQ  23
Wade et al 1987  379  Community  UK   1 m  WDI  22
 377        6  m    20
 348        12  m    18
Eastwood et al 1989  87  Rehab hosp  CND  21 d- 6 m  HDRS, GDS  50
Finset et al 1989  42  Rehab hosp  Norway  6 m  GCRD  36
Malec et al 1990  20  Rehab hosp  USA  1 m  HDRS  35
Morris et al 1990  99  rehab hosp  AU  2 m  MADRS/CIDI  35
 56        15  m    12
Parikh et al 1990  63  hospital-based  USA   1 m  HDRS, PSE,DSM-III  39
   hospital-based      2  y    39
Fedoroff et al 1991  205  hospital-based  USA   1 m  HDRS, PSE,DSM-III  41
House et al 1991  89  community  UK  1 m  PSE, DSM-III  23
 119        6  m    20
 112        12  m    16
Schubert et al 1992  18  rehab hosp  USA  1.5 m  BDI, DSM-III  72
Astrom et al 1993  80  hospital-based  SW  2 m  DSM-III  25
 77        3  m    31
 73        1  y    16
 57        2  y    19
 49        3  y    29
Schwartz et al 1993  91  rehab hosp  USA  7 m  DSM-III  40
Andersen et al 1994  285  hospital-based   DK  1 m  HDRS  21
 285        1  y    41
Burvill et al 1995  294  community  AU  4 m  PSE, DSM-III  23
Diamond et al 1995  14  rehab hosp  USA    GDS  36
Gonzalez-Torrecillas et al 1995  130  rehab hosp  Belgium  1 m  HDRS, MADRS  37
Wilkinson et al 1997  96  community  UK  5 y  HADS  36
Ng et al 1995  52  rehab hosp  Singapore   1 m  DSM-III-R  55
Herrmann et al 1998   150  hospital-based  CND  3 m  MADRS  27
 133        1  y    22
Pohjasvaara et al 1998  277  hospital-based  FIN  3 m  DSM-III-R  40
 276        15  m    45
Neau et al 1998  71  outpatient      1 y  MADRS/DSM-III  48
Kotila et al 1999  321  community  FIN  3 m  BDI  47
 311        12  m    47
Kellermann et al 1999  82  hospital-based  Hungary  1 w  BDI  15
Gainotti et al 1999  153  rehab hosp  Italy  2 m  HDRS  32
 153        4  m    60
Kauhanen et al 1999  106  rehab hosp  FIN  3 m  PSE, DSM-IIII-R  53
Paolucci et al 1999  470  rehab hosp  Italy  1.5 m  HDRS  27
van de Weg et al 1999  85  rehab hosp  Netherlands  20–40 d  DSM-III-R  35
Berg et al 2001  89  hospital-based  FIN   1 m  BDI  27
Gillen et al 2001  243  rehab hosp  USA   1 m  GDS  13
Vataja et al 2001  275  outpatient  FIN  3 m  PSE, DSM-IIII-R  40
Tang et al 2002  157  rehab hosp  China  1 m  DSM-III-R  17
Aben et al 2002  154  hospital-based  Netherlands  1 m  DSM-IV  22
 154        2  y  DSM-IV  39
Eriksson et al 2004  15747  community  Sweden  3 m  Self reported  14
Cassidy et al 2004  50  rehab hosp  Ireland  6 m  DSM-IV, HDRS  20
Mast et al 2004  195  rehab hosp  USA   1 m  DSM-III-R  36
Verdelho et al 2004  110  outpatient  France  6 m  MADRS  43
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reported vascular depression in nearly 35% (35.2%) of 
patients with cerebrovascular risk factors admitted in 
geriatric rehabilitation, but without clinical evidence of stroke 
(Mast et al 2004). In that study, a positive association was 
established between depression and increasing percentage of 
cerebrovascular risk factors (Mast et al 2004). Furthermore, 
patients with depression and subcortical vascular lesions have 
poor response to antidepressants (Simpson et al 1998), while 
might be effective dopamine acting agents or norepinephrine 
enhancing agents (Alexopoulos 2006). Thus, should vascular 
depression be recognized as a separate psychiatric disorder or 
as a diagnostic subtype of major depressive disorder? Indeed, 
Alexopoulos refined the notion of vascular depression, 
proposing a depression executive dysfunction (DED) 
disorder of late-life, but only on the basis of clinical criteria 
and regardless the etiology (Alexopoulos 2001), while 
Taylor and coworkers (2006) proposed subcortical ischemic 
depression as speciﬁ  c entity. On the other hand, while the 
former may be caused by vascular disease, the latter requires 
a subcortical vascular impairment. Further researches are 
needed to clarify these and other doubts.
Treatment studies
Although antidepressant (AD) drugs have been discovered 
many decades ago [monoamine oxidase inhibitors (MAOIs) 
in the 1950s, tricyclic antidepressant (TCA) imipramine in 
1957 and ﬁ  rst selective serotonin reuptake inhibitor (SSRI), 
ﬂ  uoxetine in 1988], most patients today do not receive 
an effective speciﬁ  c treatment. The attitude that PSD is a 
natural and inevitable condition which is not important to 
treat seems still common. General opinion appears to be 
that depression improves if the patient’s physical condition 
improves (Gustafson et al 1995). Moreover, physicians 
are often reluctant to prescribe ADs to older patients with 
relevant physical illnesses (House et al 1989), because 
of the perceived risk of side effects especially on the 
cardiovascular system, fear of drug interactions in multiple 
comorbidity, and poor experience of depression treatment 
in the elderly. However, a recent systematic review of 18 
randomized controlled trials comparing any AD drug with 
placebo or no treatment in depressed adults with a speciﬁ  ed 
physical disorder showed that ADs cause improvement 
in depressive symptoms in patients with a wide range of 
physical diseases (Gill and Hatcher 1999). In spite of these 
data, not only the studies on therapeutic approaches on PSD 
are relatively scarce, but also most of studies reported the 
effects of AD drugs only on mood disturbance. In fact, 
even if some authors suggested the favorable effect of 
AD drugs on functional recovery (Fedoroff and Robinson 
1989), there are only few studies that evaluated the impact 
of ADs on functional outcome and rehabilitation results 
(Reding et al 1986; Fedoroff and Robinson 1989; Gonzalez-
Torrecillas et al 1995; Dam et al 1996; Miyai and Reding 
1998; Paolucci et al 1999; Gainotti et al 2001; Paolucci 
et al 2001).
Table 2 reports the percentages of patients treated with 
ADs in papers regarding prevalence and clinical impact 
of PSD.
Table 1 (Continued)
 96        1  y    36
 71        2  y    24
 73        3  y    18
Vataja et al 2004  70  outpatient  FIN  3 m  PSE, DSM-IIII-R  37
Naess et al 2005  196  outpatient  Norway  6 y  MADRS  29
Paul et al 2006  441  outpatient  Australia  5 y  IDAS  17
Hackett et al 2006  739  community  NZ  6 m  GHQ  27
Jia et al 2006  5825  hospital-based,   USA  1 y  clinical  41
   retrospective
Paolucci et al 2006  1064  hospital-based  Italy  1 m  BDI, DSM-IV  22
 821        9  m    36
Townend et al 2007  125  hospital-based  Australia  1 m  HADS  16
 125        3  m  HADS  21
van de Port et al 2007  165  outpatient  Netherlands  3 y  CES-D  19
Linden et al 2007  149  outpatient  Sweden  20 m  DSM-III-R  34
Brodaty et al 2007  164  hospital-based  Australia  3 m  DSM-III-R  12
 164  outpatient  Australia  15  d  DSM-IV  21
Abbreviations: d, days; m, months; y, years; BDI, Beck Depression Inventory; CES-D, Centre for Epidemiologic Studies Depression Scale; CIDI, Composite International 
Diagnostic Interview; DSM, Diagnostic and Statistical Manual of Mental Disorder; GCRD, Global Clinical Rating of Depressed mood; GDS, Geriatric Depression Scale; GHQ, 
General Health Questionnaire; HADS, Hospital Anxiety and Depression Scale; HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery Asberg Depression Rating 
Scale; IDAS, Irritability, Depression and Anxiety Scale; PSE, Present State Examination; WDI, Wakeﬁ  eld Depression inventory; ZSRDS, Zung Self Rating Depression Scale.Neuropsychiatric Disease and Treatment 2008:4(1) 149
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The choice of optimal treatment
There is relatively little comparative information on how 
to make the choice of one AD over another, and none at all 
speciﬁ  c to PSD. Today, SSRIs are the recommended phar-
macotherapy of PSD for their favorable tolerability proﬁ  le 
(Turner-Stokes and Hassan 2002; SPREAD 2005). In fact, the 
afﬁ  nity of TCAs for a number of central receptors including 
muscarinic cholinergic and histaminergic receptors makes 
them not recommended as ﬁ  rst-line choice for treatment of 
PSD. Conversely, SSRIs have no afﬁ  nity for cholinergic or 
histaminergic receptors and thus are generally well toler-
ated, and do not have cardiovascular or sedative effects. 
However, the SSRIs are not entirely without side-effects. 
Gastrointestinal symptoms, headache, sexual dysfunc-
tion and insomnia are relatively common. Arguably, the 
most important difference between the SSRIs lays in their 
potential to cause drug- drug interactions through inhibition 
of cytochrome-P450 isoforms, which is different for each 
SSRI. Thus, ﬂ  uvoxamine is a potent CYP1A2 and CYP2C19 
inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 
inhibitor; ﬂ  uoxetine and paroxetine are potent CYP2D6 
inhibitors; sertraline is a moderate CYP2D6 inhibitor; and 
citalopram has little effect on the major cytochrome-P450 
isoforms (Hemeryck and Belpaire 2002). So, ﬂ  uvoxamine 
(CYP1A2 inhibitor) can cause an increase of blood levels 
of theophyllin or caffeine, while paroxetine and ﬂ  uoxetine 
(CYP2D6 inhibitors) an increase of concentration of TCAs 
or atypical antipsychotics. Knowledge of the CYP-isoforms 
involved in the metabolism of the co-administered drug may 
help clinicians to predict and avoid potentially dangerous 
drug- drug interactions. Expected interactions can usually be 
managed by appropriate dose adjustments and titration of the 
drug. Importantly, the use of SSRIs has been associated with 
increased risk of bleeding complications (Skop and Brown 
1996), possibly as a result of inhibition of platelet aggrega-
tion (Maurer-Spurej et al 2004). However, in a recent sys-
tematic review, Ramasubbu and colleagues (2004) observed 
that SSRI treatment had a very low rate of cerebrovascular 
adverse reactions. In particular, two case-control studies 
mentioned in that review showed no association between 
SSRI use and intracranial hemorrhage (de Abajo et al 2000; 
Bak et al 2002).
Nonpharmacological management
Today, the main therapeutic approach of PSD, and in 
particularly in subacute phase after stroke, is essentially 
pharmacological. In fact, a psychotherapeutic intervention 
is not only expensive in terms of staff time and expertise, 
but also requires several weeks before showing any clinical 
improvement. This delay may be critical for the outcome 
in a time-limited course of rehabilitation. Therefore, in the 
common clinical practice, AD treatment is the most realistic 
solution, with psychotherapeutic intervention reserved 
for those in whom ADs are either inappropriate or not 
tolerated. Regarding the effectiveness of psychotherapeutic 
interventions, methodological limitations in existing research 
prevent a conclusion as any psychological intervention has 
empirical support for its effectiveness (Gordon and Hibbard 
1997; Kneebone and Dunmore 2000). On the other hand, 
cognitive behavioral therapy has shown some promising 
results that make it worthy of further exploration (Lincoln 
et al 1997; Lincoln and Flannaghan 2003).
Table 2 Percentages of patients treated with antidepressant in studies on prevalence of PSD
Authors n  Population  Country  %  patients
       treated
Sinyor et al 1986  64  Rehab hosp  CND  33
Ebrahim et al 1987  149  hospital-based  UK  15
Parikh et al 1990  63  hospital-based  USA  8
Herrmann et al 1998  150  hospital-based  Canada  19
Pohjasvaara et al 1998  277  hospital-based  FIN  39
Kotila et al 1999  321  community  FIN  17
Kauhanen et al 1999  106  rehab hosp  FIN  36
Paolucci et al 1999  470  rehab hosp  Italy  100
van de Weg et al 1999  85  rehab hosp  Netherlands  20
Eriksson et al 2004  15747  community  Sweden  49
Cassidy et al 2004  50  rehab hosp  Ireland  60
Paul et al 2006  441  outpatient  Australia  22
Paolucci et al 2006  1064  hospital-based  Italy  49
Jia et al 2006  5825  hospital-based,   USA  63
   retrospectiveNeuropsychiatric Disease and Treatment 2008:4(1) 150
Paolucci
Controlled pharmacological studies
Controlled studies on the effectiveness of ADs in PSD are 
relatively few, and they are essentially related to the use of 
TCAs or SSRIs (Table 3). Data on usefulness of new dual-
component ADs are still not available, to our knowledge.
In a recent Cochrane review, only 7 trials with AD, with 
a total of 615 patients, entered the meta-analyses (Hackett 
et al 2004, 2005a). The results of meta-analyses showed that 
there was evidence of a improvement in depression rating 
scales, but not in terms of a complete remission of depression 
following stroke (Hackett et al 2004, 2005a). However, some 
methodological aspects of this review have been criticized. 
In particular, Chen and Guo (2006) suggested that the overall 
effects of AD treatment in term of various depression scores 
would better be estimated by separating the pretreatment and 
post-treatment instead of calculating the mean differences. In 
this fashion, AD treatments were effective in patients after 
the stroke in term of reducing the symptoms of depression. 
Moreover, can the concept of remission be applied in patients 
with depression in comorbidity? In fact, the idea of remission 
refers to a return to symptom-free state or premorbid levels 
of functioning (Bakish 2001). Such a model for depression 
in comorbidity is obviously arduous to obtain, because of 
the presence of somatic symptoms.
In another recent review, involving six pharmacological 
studies, there was evidence that ADs signiﬁ  cantly improved 
mood, also in spite of a relevant number of dropouts due 
to side effects treatment, especially with heterocyclic ADs 
(Bhogal et al 2005). So, it appears that both TCAs and SSRIs 
may be effective in the treatment of PSD, although the latter 
may produce fewer side-effects.
Two randomized, double-blinded, placebo-controlled 
studies have evaluated the effectiveness of nortriptyline, a 
tricyclic drug (Lipsey and Robinson 1984; Robinson et al 
2000). In the last one, the effectiveness of ﬂ  uoxetine was also 
assessed (Robinson et al 2000). In both studies, a signiﬁ  cant 
improvement in depression symptoms was observed in the 
treated groups as compared to controls. In particular, in 
Table 3 Controlled studies on treatment of post-stroke depression
Authors No Treatment studied Design Time 
from 
stroke
Trial 
length 
Outcome 
measures
Results
Lipsey et al 1984 34 nortryptiline vs placebo DB  18 m 4–6 w HDRS, ZSRDS nortriptyline more effective than placebo in 
reduction of depression
Reding et al 1986 27 trazodone vs placebo DB  6 w ∼4–5 w ZSRDS trazodone trend towards better functional status
Andersen et al 1994 66 citalopram vs placebo DB  2–52 w 16 w HDRS citalopram more effective than placebo in reduc-
tion of depression
Lauritzen et al 1994 20 Imipramine+mianserin vs 
desipramine+mianserin
DB   3 m 6 w HDRS Imipramine + mianserin more effective than 
desipramine + mianserin in reduction of depres-
sion
Robinson et al 2000 56 nortryptiline vs ﬂ  uoxetine
vs placebo
DB  4–16 w 12 w HDRS nortriptyline produced a signiﬁ  cantly higher 
response rate than ﬂ  uoxetine or placebo 
Wiart et al 2000 31 ﬂ  uoxetine vs placebo DB   3 m 6 w MADRS ﬂ  uoxetine more effective than placebo in reduc-
tion of depression
Fruehwald et al 2003 54 ﬂ  uoxetine vs placebo DB   2 w 3 m HDRS, BDI ﬂ  uoxetine more effective than placebo at 
18-month follow-up evaluation
Rampello et al 2004 74 citalopram vs reboxetina DB  12 m 16 w HDRS, BDI citalopram better in anxious depressed patients, 
reboxetine more effective in retarded depressed 
patients.
Murray et al 2005 123 sertraline vs placebo DB  3 d – 1y 26 w MADRS, EDS sertraline superior only in emotional distress, 
emotionalism and QoL
Choi-Kwon et al 2006 152 ﬂ  uoxetine vs placebo DB  14 m 3 m BDI, clinical, 
STAS
ﬂ  uoxetine more efﬁ  cacious only in the treatment 
of emotional incontinence  and anger proneness.
Abbreviations: w, weeks; m, months; y, years; DB, double-blind; BDI, Beck Depression Inventory; HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery Asberg 
Depression Rating Scale; QoL, Quality of Life; STAS, Spielberger Trait Anger Scale.Neuropsychiatric Disease and Treatment 2008:4(1) 151
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the ﬁ  rst study a mean baseline to endpoint improvement in 
HDRS score of 79% was observed in patients treated with 
nortriptyline as compared with an improvement of 40% in 
patients treated with placebo (Lipsey and Robinson 1984). 
In the second study, the mean improvement in HDRS score 
was higher in depressed patients treated with nortriptyline 
(60% vs. 9% for patients treated with ﬂ  uoxetine and 30% with 
placebo) (Robinson et al 2000). Furthermore, in the study by 
Robinson and colleagues (2000), but not in that by Lipsey 
and Robinson (1984), a better recovery in activities of daily 
living for nortriptyline group was observed. However, there 
was disagreement regarding drop-out rate: higher among 
those treated with nortriptyline (38%) in the study by Lipsey 
and Robinson (1984), and among those treated with ﬂ  uox-
etine (40%) in the study by Robinson and colleagues (2000). 
However, in this latter study, such high drop-outs rate with 
ﬂ  uoxetine might have been due to the relative high dose (up 
to 40 mg per day) of ﬂ  uoxetine used (Robinson et al 2000). 
Moreover, the results of this study fostered the discussion 
about methodological problems (Van de et al 2003).
Two double-blinded controlled studies have assessed the 
effectiveness of citalopram, a selective serotonin reuptake 
inhibitors (SSRI), the ﬁ  rst one vs. placebo and the second one vs. 
noradrenergic drug reboxetine (Andersen et al 1994a; Rampello 
et al 2004). In both studies, citalopram showed good efﬁ  cacy 
and tolerability. In the ﬁ  rst study, a mean baseline to endpoint 
improvement in HDRS score of 45.5% was observed in patients 
treated with citalopram as compared with an improvement of 
16% in patients treated with placebo. Although the drop-out rate 
was higher in citalopram group, the reported side effects were 
relatively well tolerated and transient (Andersen et al 1994a). 
In the second trial, Rampello et al showed that citalopram 
exhibited greater efﬁ  cacy in anxious depressed patients, while 
reboxetine was more effective in retarded depressed patients. 
No severe side effects were recorded during the study. The 
drop-out rate was similar between groups, too (three for both 
treatment) (Rampello et al 2004).
Four studies evaluated the effectives of fluoxetine, 
another SSRI agent, both on early and late phase after stroke 
(Robinson et al 2000; Wiart et al 2000; Fruehwald et al 
2003; Choi-Kwon et al 2006). The results of these studies 
are conﬂ  icting. In particular, while a positive action on mood 
even in early phase was observed by Wiart and colleagues 
(2000), with a mean improvement in MADRS score of 58% 
for ﬂ  uoxetine group vs. 31% in placebo group, Fruehwald 
and coworkers (2003) observed such positive action only 
in the follow-up. Moreover, Choi-Kwon and colleagues 
(2006) found that ﬂ  uoxetine was effective only on emotional 
incontinence and anger proneness, while Robinson and 
coworkers (2000) above described a lower effectiveness in 
comparison with nortriptyline. The drop-out rates were also 
conﬂ  icting: Fruehwald observed no drop-outs during the 
treatment, Wiart only two (13.3%) in patients treated with 
ﬂ  uoxetine, while Choi-Kwon 19.7% in ﬂ  uoxetine group and 
15.8% in placebo group (Wiart et al 2000; Fruehwald et al 
2003; Choi-Kwon et al 2006).
Sertraline, another SSRI AD, showed no advantage in 
comparison to placebo either on major depressive episode 
or minor depressive disorder (Murray et al 2005). In fact, 
both groups improved substantially, with no differences 
between the treatments, either for major depressive episode 
or minor depressive disorder, or for short- or long-term 
antidepressant effect and neurologic outcome. However, 
the compound showed a signiﬁ  cantly positive effect only on 
QoL at follow-up at week 26. No serious side effects were 
observed (Murray et al 2005).
A study by Lauritzen and coworkers (1994) compared 
the efﬁ  cacy of two TCAs, desipramine against imipramine, 
both drugs combined with mianserin. The doses of the drugs 
were ﬂ  exible, with side-effects as a guide during treatment. 
Imipramine treatment was more effective than desipramine 
in reducing depressive symptoms evaluated by means of 
Melancholia Scale, but not by means of HDRS. However, a 
large proportion (35%) of the sample was lost in the follow-up, 
particularly in the desipramine group (Lauritzen et al 1994).
Lastly, Reding and colleagues (1986) evaluated the 
response of depressive symptoms to trazodone in a con-
trolled trial vs. placebo. They showed that trazodone treated 
patients had a tendency to increase in autonomy in ADL 
measured by the Barthel index compared to patients treated 
with placebo. However, a high drop-out rate due to side 
effects was observed in both groups of patients. In particular, 
twelve patients discontinued the study: six patients from the 
trazodone group (4 sedation, 1 eye discomfort, 1 refusal), 
but also six patients in placebo group (4 sedation, 1 nausea, 
1 dizziness). Moreover, because of the particular study 
design, it was not possible to compare the improvement in 
depression scores of both groups.
Other studies
There are other studies that evaluated the impact of different 
type of ADs on functional outcome and rehabilitation results. 
Today, AD therapy may be beneﬁ  cial to functional recovery 
but it cannot abolish the detrimental effect of depression on 
functional outcome (Gonzalez-Torrecillas et al 1995; Dam 
et al 1996; Miyai and Reding 1998; Gainotti et al 2001).Neuropsychiatric Disease and Treatment 2008:4(1) 152
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In a nonrandomized study published in 1995, Gonzalez-
Torrecillas and colleagues showed that treated PSD patients 
(with nortriptyline or ﬂ  uoxetine) had not only a better mood, 
but also a better functional and cognitive outcome com-
pared to untreated PSD patients. Moreover, the study was 
nonblinded: ﬂ  uoxetine was given to patients with cardiac 
defects and nortriptyline to those without. Both drugs made 
similar gains in both mood and functional ability (Gonzalez-
Torrecillas et al 1995).
Some years later Gainotti and colleagues (2001) con-
ﬁ  rmed that functional recovery of nontreated depressed 
patients was poorer than the nondepressed and the depressed 
but treated patients.
Dam and colleagues (1996) observed that patients 
treated with ﬂ  uoxetine had better rehabilitation results in 
comparison with those of patients treated with norepinephrine 
reuptake blocker maprotiline or placebo. These effects were 
not related to the speciﬁ  c antidepressant action. Moreover, 
both groups treated with Ads showed a signiﬁ  cant baseline 
to endpoint mean improvement in HDRS score (ﬂ  uoxetine 
30%, maprotiline 18%). Mean improvement in placebo 
group was 12%.
This favorable role of ﬂ  uoxetine on functional status was 
conﬁ  rmed also by another study, in which patients treated 
with ﬂ  uoxetine or trazodone showed a better improvement 
on functional independence measure compared with patients 
treated with desipramine (Miyai and Reding 1998).
Since serotonin (5-HT) stimulates motor function, there 
are some studies that investigated the hypothesis that a phar-
macological potentiation of 5-HT neurotransmission may 
improve motor function in healthy subjects and recovery 
in poststroke patients (Pariente et al 2001; Loubinoux et al 
2002). In particular, in a double-blind, crossover, placebo-
controlled study on 8 patients with pure motor hemiparesis, 
a single dose of ﬂ  uoxetine was able to signiﬁ  cantly improve 
motor skills of the affected side (Pariente et al 2001). How-
ever, other experimental reports (after focal ischemia in 
rats) did not conﬁ  rm these adjuvant action of ﬂ  uoxetine on 
recovery of motor function (Windle and Corbett. 2005).
ADs may reduce post stroke mortality. In a 9 year follow-
up study, treatment with ﬂ  uoxetine or nortriptyline for 
12 weeks during the ﬁ  rst 6 months after stroke signiﬁ  cantly 
increased the survival of both depressed and nondepressed 
patients (Jorge et al 2003).
Lastly, there are few studies on the usefulness of 
new dual-agents SNRIs (serotonin and norepinephrine 
reuptake inhibitors), as venlafaxine or milnacipran and 
duloxetine (Dahmen et al 1999; Yamakawa et al 2005), but 
methodological problems (open-label studies and with small 
case-series) reduce the power of these data.
Prevention of PSD
A recent Cochrane review, evaluating data from nine trials 
(11 comparisons) involving different pharmaceutical agents, 
and three trials of psychotherapy, found no clear effect of 
either pharmacotherapy or psychotherapy on the prevention 
of depressive illness or disability (Anderson et al 2004). 
Moreover, data from a more recent trial showed that sertraline 
treatment, 50 mg/day, had no advantage in comparison to 
placebo in preventing PSD (Almeida et al 2006).
A more recent meta-analysis published in 2007, evaluating 
10 randomized clinical trials, with a total of 703 nondepressed 
stroke patients, found that ADs prophylaxis was associated 
with a signiﬁ  cant reduction in the occurrence rate of newly 
developed poststroke depression (12.54% in the treated group 
vs 29.17% in control group) (Chen et al 2007).
Length of treatment
At present, there is no scientiﬁ  c evidence regarding the optimal 
length of treatment of PSD. Many of the available trials 
terminate at six weeks, but withdrawal at this stage may result 
in relapse. In a recent review, Turner-Stokes and Hassan (2002) 
recommended carrying on AD treatment for 4–6 months, 
followed by slow withdrawal. The same length of AD is rec-
ommended by the Italian Guidelines for stroke management 
SPREAD (Stroke Prevention and Awareness Diffusion), but 
the power of this recommendation is weak (grade GPP, based 
on the clinical experience of the guideline development group, 
without research evidence) (SPREAD 2005).
Conclusions
Presently, there are still too many questions about PSD and 
too few answers. Crucial unresolved issues are essentially 
related to correct diagnostic and therapeutic approaches. 
There is clear evidence that an AD treatment may improve 
depression but it is unable to produce a full clinical remis-
sion or prevent the onset of diagnosable depressive illness. 
Moreover, data available regarding the choice or the length 
of optimal treatment are still not conclusive.
Because the beneﬁ  ts of AD therapy are potentially great, not 
only on mood but also on functional recovery, there is a pressing 
need for further research in this area of stroke medicine.
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